The headline is recognition: heavy periods are common, they're treatable, and most women don't know they qualify. Treatment cuts bleeding by 70-90% with medication alone — no surgery for most. The hidden tax is iron depletion, which causes the fatigue and brain fog and hair shedding long before anaemia shows up on a standard blood test. Action is one clinic visit and a ferritin level. Most of the women's-health territory worth knowing about lives behind this door.
The medical definition of a heavy period was set in a 1966 Swedish population study: more than 80 millilitres of blood per cycle — about a third of a coffee cup. The cutoff was the 95th percentile of normal. Nobody, including doctors, asks women to measure their menstrual output in millilitres, so the practical definition shifted to one a woman can actually use: bleeding heavy enough to interfere with your life NICE 2018. Both definitions describe the same population — and crucially, women's own sense of "is this heavy?" tracks measured blood loss only loosely. About half the women who think their periods are heavy don't quite hit 80 mL; about half the women who do, think their periods are fine Higham 1990.
The practical shorthand a clinician will use:
- Soaking through a pad or tampon in under two hours, repeatedly
- Needing to double up — pad plus tampon, or two pads — to hold a normal day
- Passing blood clots larger than a grape
- Bleeding longer than seven days
- Flooding through clothes or bedding
- Planning your week around your period — staying home, avoiding white clothing, calling in sick
Any of those, persistently, qualifies. You don't have to hit all of them. If you're unsure, tracking a couple of cycles against that list — days of bleeding, how often you change, any flooding or clots — is what turns a hunch into the documentation that gets it taken seriously in the clinic.
Underneath the symptom is a short list of causes, organised by gynecologists under the acronym PALM-COEIN. PALM is structural — something physically there that wasn't there before. COEIN is non-structural — something the body is doing wrong rather than something it's grown.
Fibroids are the most common single cause. Roughly one in four women of reproductive age has at least one on imaging, though only a fraction are symptomatic Stewart 2015. They're estrogen-fed, they often grow slowly through the thirties and forties, and they cause heavy bleeding by some combination of stretching the uterine lining surface, distorting blood vessels, and interfering with the muscular squeeze that normally limits flow. Black women develop fibroids earlier, larger, and more symptomatically than white women — about three times the prevalence Stewart 2015.
Adenomyosis is the underdiagnosed sibling. The endometrial lining grows into the uterine muscle itself, producing an enlarged, tender uterus and a triad of heavy bleeding, painful periods, and — if you're trying — fertility trouble. A 2017 review put prevalence around 20% on modern imaging criteria; for decades it could only be diagnosed after hysterectomy, which is why most women have never heard of it. Transvaginal ultrasound now catches it about as well as MRI does.
A smaller fraction of cases — somewhere between one in twenty and one in five women evaluated for chronic heavy bleeding — turn out to have an inherited bleeding disorder, most often von Willebrand disease James 2009. The tell is heavy bleeding since the first period, often with heavy bleeders in the family. Many of these women have never been formally diagnosed because nobody asked.
What it actually costs you
The bleeding is the visible part. The invisible part is what bleeding too much, every month, for years, does to the body's iron supply — and that is where most of the felt experience of having heavy periods actually comes from.
Heavy menstrual bleeding is the leading cause of iron deficiency in women under fifty in high-income countries Mansour 2021. The arithmetic is unforgiving: a normal period loses something like 30 to 40 mL of blood; a heavy one loses two to ten times that. Iron lost in blood has to be replaced from food, and the math of replacing it from a normal diet barely works out for a woman with a normal period, let alone a heavy one. Stores deplete. Symptoms appear.
The thing to understand: anaemia is the late finding. Long before haemoglobin drops below the lab's anaemia line, ferritin — the body's iron storage protein — has been falling. And the symptoms of low ferritin are the symptoms most women with heavy periods describe:
- Persistent fatigue that doesn't lift with rest
- Exercise that used to feel fine, now feels like wading
- Brain fog, dropped words, attention that won't catch
- Hair shedding in the shower
- Restless legs at night
- A heart that pounds going up stairs
- The week before the period, the week of, the week after — a quarter of every month spent at half-power
The standard "your bloodwork is normal" reading misses this entirely, because the standard panel measures haemoglobin and not ferritin. A woman can have a normal full blood count and a ferritin of 8 — well into the territory where symptoms are reliable Mansour 2021.
Beyond iron, the bleeding itself extracts a tax that shows up in productivity data. A 2019 Dutch survey of over 32,000 women found a 33% mean productivity drop on bleeding days — mostly presenteeism, the version of work where you're at the desk but your brain isn't — averaging close to nine days a year of lost output per woman. A US systematic review estimated the indirect cost of heavy menstrual bleeding alone — work missed, work done badly — at up to $12 billion a year.
The picture, if you zoom out: a woman with untreated heavy periods spends one week of every month with measurably reduced energy and cognition, the next week recovering, and the remaining two operating below where she should be because her iron stores never quite refill. Then she does it again. For thirty years.
What women get told that's wrong
The single most damaging belief is that this is just how your body is. It is the reason women wait an average of years before presenting, and it is reinforced by the fact that heavy bleeders often have heavy-bleeding mothers and sisters — when everyone you grew up around bled the same way, the read isn't "we share a treatable condition," it's "this is normal in our family." Pattern inheritance through a household isn't a medical defense of the pattern James 2009. About four in five women with heavy menstrual bleeding never seek care for it.
The other recurring misreads:
- "My bloodwork was normal so my iron is fine." Standard bloodwork measures haemoglobin. Iron stores are measured by ferritin, which is a separate test you have to ask for. Iron deficiency without anaemia is at least twice as common as iron-deficiency anaemia, and it produces most of the same symptoms Mansour 2021.
- "The only fix is a hysterectomy." Hysterectomy is the definitive option when other things have failed, and it is the right answer for some women. It is not the first or second or third line. The hormonal IUD reduces bleeding by 70–95% in most women who keep it in, with no surgery Bofill Rodriguez 2020.
- "Hormonal IUDs are for birth control." The 52 mg levonorgestrel IUD is specifically approved for heavy menstrual bleeding. Contraception is a side benefit, not the indication.
- "It'll get better when I'm older." Sometimes — but adenomyosis and fibroids often worsen through the late thirties and forties, and the symptom load is highest in the decade before menopause, not the lowest Vannuccini 2017.
What to actually do
The action is small: get evaluated. The workup is straightforward, mostly bloodwork plus an ultrasound, and the treatment options that come out of it are well-evidenced and don't require surgery for most women.
Treatment is a menu. Most women never need surgery; the medical options handle the majority of cases.
- The hormonal IUD (52 mg levonorgestrel — branded Mirena, Liletta) is the strongest medical option and the first-line recommendation in most guidelines. It releases a small daily dose of progestin directly into the uterus, thinning the lining over a few months. The ECLIPSE trial, which followed 571 UK women referred by their GPs, found bigger improvements in quality-of-life scores than any oral medication, and the 10-year follow-up showed the difference held. Bleeding reduction is typically 70 to 95% Bofill Rodriguez 2020. The first three to six months are unpredictable — spotting, irregular bleeding — and then most users settle into very light or absent periods.
- Tranexamic acid (Lysteda, generic) is a pill taken only during your period — three or four times a day for the heaviest days. It blocks clot breakdown so menstrual blood clots up sooner. A 2010 placebo-controlled trial found a 40% reduction in measured blood loss and significant improvements in social, physical, and work limitations. Useful if you want non-hormonal, episodic treatment.
- NSAIDs — mefenamic acid (500 mg three times daily during menses), naproxen — reduce bleeding by 20 to 50% and treat cramps at the same time Bofill Rodriguez 2019. Cheapest option; addresses two symptoms at once.
- Combined hormonal contraceptives (the pill, the patch, the ring) reduce bleeding by 35–70% and are a good fit if you also want contraception.
- Surgical options — endometrial ablation (an outpatient procedure that destroys the uterine lining) or hysterectomy — are reserved for medication failure, fertility-complete women, or specific structural cases. The HEALTH trial compared the two and found both effective; ablation has lower morbidity but a real reintervention rate over time.
Where treatment goes wrong in practice
The most common pattern is incomplete workup. Common ways:
- Ferritin not checked. A "normal CBC" gets used as evidence that iron stores are fine. They aren't necessarily — ferritin is the test, not haemoglobin Powers 2017.
- Ultrasound skipped. Fibroids, polyps, and adenomyosis change the management decision. Without imaging, the workup is incomplete.
- Coagulation screen never ordered in a woman who bled heavily from her first period. Five to twenty-four percent of chronic heavy bleeders have an undiagnosed inherited bleeding disorder James 2009, and standard treatments often work better with hematology co-management.
On the treatment side:
- The hormonal IUD pulled too early. The bleeding-pattern adjustment phase lasts three to six months. Many women who would do well on it discontinue inside the first three because the irregular spotting looks like failure. It isn't — the major reduction kicks in after the lining thins Bofill Rodriguez 2020.
- Tranexamic acid taken as-needed instead of scheduled. It works because it's in the blood across the heavy days; one tablet on the worst day does little. Scheduled dosing through the bleeding window is what produces the trial-level effect.
- Iron stopped at "haemoglobin normal." Haemoglobin recovers first; ferritin takes months longer. Stopping too early means the symptoms return within a few cycles and the next bloodwork looks like a relapse. Treat to ferritin, not haemoglobin.
What changes if you treat it
The first month is usually the unimpressive one. A hormonal IUD spends three to six months making the bleeding pattern worse before it settles. Tranexamic acid cuts the heavy days roughly in half the first cycle you use it properly. Iron, taken correctly, doesn't move the symptoms much for the first two or three weeks.
By month three, the pattern most women describe is something like: I forgot it was period week. Not because the period vanished, but because it stopped being the thing that organised the month. The pad-and-tampon double-up disappears. White trousers come back. The plans you used to cancel hold.
By month six, the iron story catches up to the bleeding story. The fatigue that you'd been calling your personality starts to lift. Stairs are stairs again. The afternoons you'd been masking with caffeine become afternoons you actually have Mansour 2021. People close to you tend to notice this part before you do — partners and friends mention you seem like yourself again, before you've consciously identified what changed.
By the end of the first year, the structural picture is clearer. If the underlying cause was fibroids or adenomyosis, ongoing treatment manages the bleeding indefinitely. If it was ovulatory dysfunction, treating the cause (PCOS management, thyroid replacement) often resolves the bleeding pattern. The ECLIPSE 10-year follow-up showed most women who started a hormonal IUD stayed on it or stepped to a similar option, and only a minority moved to surgery.
The longer arc is the part that's hard to feel from inside it: thirty years of bleeding more than you should is thirty years of running iron-deficient, doing roughly a quarter of your life at half capacity. Closing that gap closes a quarter of your life.
When to escalate faster, and treatment cautions
Some bleeding patterns warrant a faster track than the routine workup. See a clinician promptly, not at the next annual, if any of these apply:
The treatments have their own cautions:
- Tranexamic acid shouldn't be used if you've had a blood clot, are on combined hormonal contraception alongside (a relative caution — discuss with your clinician), or have certain clotting disorders.
- The hormonal IUD isn't placed when there's an active pelvic infection, unexplained vaginal bleeding that hasn't been worked up, current breast cancer, or suspected uterine cancer.
- NSAIDs aren't a good fit with stomach ulcers, significant kidney disease, or some bleeding disorders.
- Combined hormonal contraceptives are off the table with migraine with aura, smoking after 35, history of blood clots, or several cardiovascular conditions.
Related territory
Things worth looking at next, if any of them apply:
- Iron deficiency without anaemia — the symptom story when the ferritin is low but the haemoglobin hasn't fallen yet. Heavy menstrual bleeding is the most common cause, but not the only one.
- Iron supplementation — the practical question of how to refill stores: oral ferrous sulphate, alternate-day dosing, when intravenous iron is the right move.
- Painful periods (dysmenorrhea) — often travels with heavy bleeding, especially in adenomyosis and endometriosis. Different mechanism, overlapping treatment menu.
- Endometriosis — the sibling condition. Shares some treatments with adenomyosis; pelvic pain is more prominent than bleeding volume.
- Uterine fibroids — when the bleeding traces to fibroids, the menu of fibroid-specific treatments (myomectomy, uterine artery embolisation, GnRH-modulators) opens up.
- Polycystic ovary syndrome (PCOS) — a common cause of irregular heavy cycles via the ovulation route.
- Perimenopause — bleeding pattern changes in the late forties have their own diagnostic playbook.
- — Month after month of heavy bleeding is a classic route to depleted iron — worth checking ferritin.
- — A hormonal IUD or pill is often the simplest fix — it can cut the bleeding sharply or stop periods altogether.
- — Documenting how heavy and how long is the first step that gets heavy bleeding taken seriously.
- — The hidden tax of heavy periods is iron loss — check ferritin, not just a standard blood count.
- — Fibroids are one of the most common reasons periods turn heavy; worth ruling in or out with a scan.
- — Adenomyosis is a frequent, under-diagnosed cause of heavy, painful periods — ask for the ultrasound.
- — If periods are heavy, your iron is probably leaking out faster than food replaces it; ferritin and a supplement help.
- — Heavy periods quietly drain iron; the MCV/RDW pattern on a routine blood test is often the first hard evidence.
- — Heavy bleeding often shows up in perimenopause; it's a fixable part of the transition, not a given.
- — If heavy bleeding comes with crippling pain, ask about endometriosis — it's commonly missed for years.
Substance and claimed effects
Heavy menstrual bleeding (HMB), historically termed menorrhagia, is excessive menstrual blood loss that interferes with a woman's physical, social, emotional, or material quality of life NICE 2018. The objective threshold from the Hallberg population study is >80 mL per cycle (95th percentile of 476 Swedish women) Hallberg 1966; modern definitions are subjective and quality-of-life-based, because objective measurement is impractical outside research NICE 2018. The entry's scope is HMB in adult women of reproductive age — the symptom, its objective and subjective definitions, the structural and systemic causes catalogued under FIGO PALM-COEIN, and the downstream consequences: iron depletion (with and without anemia), energy and cognitive cost, daily and work impact, and quality-of-life burden. Claimed effects across catalogue dimensions: substantial drag on energy and focus via iron deficiency, meaningful short-term health burden, mood and quality-of-life cost, and — once recognised and treated — large reversibility of all of the above.
Evidence by addressing question
Mechanism
HMB is mechanism-plural; FIGO's PALM-COEIN framework sorts causes into structural (Polyps, Adenomyosis, Leiomyoma, Malignancy/hyperplasia) and non-structural (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not otherwise classified). The two highest-prevalence structural causes:
- Leiomyomas (fibroids) — benign monoclonal smooth-muscle tumours of the myometrium, estrogen- and progesterone-responsive. Present in roughly 25% of reproductive-age women on imaging; symptomatic in a substantial minority Stewart 2015Donnez 2016. Submucosal and intramural fibroids drive HMB via expanded endometrial surface area, distortion of vasculature, impaired myometrial contraction, and altered local hemostasis Stewart 2015.
- Adenomyosis — ectopic endometrial glands and stroma within the myometrium. Prevalence estimates range 20–35% on histology after hysterectomy and on modern imaging criteria; classic triad is HMB, dysmenorrhea, and an enlarged tender uterus Vannuccini 2017. Transvaginal ultrasound has reached sensitivity/specificity comparable to MRI for diagnosis Vannuccini 2017.
Non-structural mechanisms with meaningful prevalence: ovulatory dysfunction (PCOS, perimenopause, thyroid disease — unopposed estrogen producing thickened, irregularly shed endometrium Krassas 2010); endometrial-level dysregulation (altered prostaglandin balance and impaired local hemostasis); iatrogenic (copper IUDs, anticoagulants); and inherited bleeding disorders, most commonly von Willebrand disease James 2009.
Evidence (epidemiology and burden)
Prevalence depends sharply on definition: objective measurement (>80 mL/cycle by alkaline-hematin) yields 9–14%; subjective self-report yields 20–52%, with one population-based UK study at 15.2% under the NICE quality-of-life definition NICE 2018Hallberg 1966. Women's perception of their own bleeding correlates poorly with measured loss: only 40–50% of women who report HMB exceed the 80 mL threshold, and conversely many women who do exceed it consider their periods normal Higham 1990. The PBAC chart (Higham 1990) — a pictorial scoring tool with ≥100 the operational cutoff — achieves >80% sensitivity and specificity for objectively-measured menorrhagia and remains the standard semi-quantitative research tool. Population-level burden: in the UK, ~1.5 million GP consultations per year for menstrual complaints, with direct annual costs exceeding £65 million NICE 2018. In the US, estimated annual direct cost ~$1 billion and indirect cost (work absence, productivity) up to $12 billion Liu 2007Frick 2009.
Stakes — downstream consequences
HMB is the leading cause of iron deficiency and iron-deficiency anemia in premenopausal women in high-income countries Mansour 2021. The pathway has two stages worth separating:
- Iron deficiency without anemia appears first, as ferritin stores deplete to maintain hemoglobin. Symptoms appear well before hemoglobin falls below the anemia threshold: persistent fatigue, exercise intolerance, brain fog and reduced cognitive performance, hair shedding, restless legs, palpitations, and impaired mood Mansour 2021. In adolescents with HMB, fewer than half of iron-deficient cases are detected by hemoglobin alone — ferritin is the more sensitive marker Powers 2017.
- Iron-deficiency anemia follows when bleeding outpaces repletion. Prevalence among women with HMB ranges 35–60% depending on population Mansour 2021Powers 2017. In a Swedish cohort with von Willebrand disease and HMB, 45% had ferritin <30 μg/L and 18% had hemoglobin <12 g/dL.
Functional impact, separable from anemia: women with HMB report ~9 days/year of lost productivity (mostly presenteeism — showing up but accomplishing less), 33% mean productivity drop on bleeding days, restricted social and physical activity, sleep disruption from overnight changing, and meaningful anxiety/depression burden tied to the symptom itself Schoep 2019Liu 2007. Sexual-function and relationship effects are documented in qualitative studies.
Protocol — diagnostic workup and treatment
Diagnostic workup per NICE 2018 and ACOG 2019: history (PBAC if formalising), full blood count and ferritin (always — even when not visibly anemic), TSH if ovulatory dysfunction suspected, transvaginal ultrasound for structural causes, endometrial biopsy in women ≥45 or with persistent HMB unresponsive to treatment or with risk factors for hyperplasia/malignancy. Coagulation screen — including von Willebrand factor — when HMB has been present since menarche, in adolescents, with personal/family bleeding history, or with negative imaging.
First-line medical treatment is the levonorgestrel-releasing intrauterine system (LNG-IUS, 52 mg — Mirena/Liletta). The ECLIPSE primary-care RCT (Gupta 2013) randomised 571 women to LNG-IUS or usual medical treatment; LNG-IUS produced significantly greater improvements in Menorrhagia Multi-Attribute Scale scores at 2 years, sustained out to 10-year follow-up (Kai 2022). Cochrane meta-analysis: LNG-IUS reduces menstrual blood loss by 71–95% versus baseline and is superior to oral medical alternatives Bofill Rodriguez 2020. Other medical options:
- Tranexamic acid (antifibrinolytic, oral, 1 g three to four times daily during menses): blood-loss reduction 34–59% versus placebo; Lukes 2010 RCT showed 40.4% reduction (vs. 8.2% placebo, p<0.001) and significant improvement in patient-reported limitations on social, physical, and work activity.
- NSAIDs (mefenamic acid 500 mg three times daily, naproxen): 20–50% blood-loss reduction; less effective than LNG-IUS and tranexamic acid but addresses dysmenorrhea concurrently Bofill Rodriguez 2019.
- Combined hormonal contraceptives: blood-loss reduction ~35–70%; first-line when contraception is also desired.
- Oral progestins: high-dose for acute control; less effective than LNG-IUS for chronic management.
Surgical options after medical failure or when fertility preservation is not required:
- Endometrial ablation — outpatient, ~85% bleeding satisfaction at short-term follow-up; one-third require further intervention within ~5 years; hysterectomy avoidance ~90% at 1–2 years, decaying over time Cooper 2019.
- Myomectomy / uterine artery embolisation — fibroid-specific, fertility-sparing where relevant Stewart 2015.
- Hysterectomy — definitive; reserved for failure of less-invasive options or where pathology demands it. The HEALTH trial (Cooper 2019) showed laparoscopic supracervical hysterectomy modestly outperformed second-generation endometrial ablation on patient-reported satisfaction at 15 months, at the cost of greater procedural morbidity.
Iron repletion runs in parallel to source treatment — oral ferrous sulphate or equivalent for mild–moderate deficiency, intravenous iron (ferric carboxymaltose, ferric derisomaltose) for severe deficiency, intolerance, or rapid repletion need Mansour 2021.
Contraindications and red flags
Red flags requiring expedited evaluation: postcoital bleeding, intermenstrual bleeding (especially after age 40), postmenopausal bleeding, pelvic mass on exam, age ≥45 with new HMB (rule out hyperplasia/malignancy via biopsy), hemodynamic instability with acute bleed. Tranexamic acid is contraindicated in active thromboembolic disease and in women with strong VTE history; LNG-IUS contraindicated in active pelvic infection, undiagnosed uterine bleeding, suspected gynecologic malignancy, current breast cancer. NSAIDs contraindicated in peptic ulcer disease, severe renal impairment, certain bleeding diatheses. Combined hormonal contraceptives contraindicated in women with migraine with aura, history of VTE, smoking ≥35, and several cardiovascular conditions.
Misconceptions
The dominant misconception is that heavy periods are normal — particularly in families where mother and sisters bled heavily, since pattern inheritance reinforces the read of "this is just how my body is" James 2009. Qualitative work shows women delay presentation for years, often citing normalisation as the primary reason; ~80% of women with HMB do not seek medical care for it. Other misconceptions: that ferritin doesn't matter if hemoglobin is normal (it does — symptoms appear well before frank anemia) Powers 2017; that hysterectomy is the only fix (LNG-IUS makes most cases medically manageable) Gupta 2013; that hormonal IUDs are only for contraception (the 52 mg LNG-IUS is FDA-approved specifically for HMB).
Failure modes
Common failure patterns: hemoglobin-only screening missing iron-deficient women with normal Hb; structural workup skipped, missing fibroids or polyps; coagulopathy workup skipped in women with lifelong HMB, missing von Willebrand disease (5–24% prevalence among women with chronic HMB) James 2009; tranexamic acid prescribed but used as-needed rather than scheduled across menses; LNG-IUS discontinued early during the 3–6 month bleeding-pattern adjustment phase that precedes the major reduction Bofill Rodriguez 2020; iron repletion stopped when hemoglobin normalises, before ferritin stores are refilled (recurrence within months).
Audience
HMB is by definition a condition of women with menstrual cycles — premenarchal and postmenopausal bleeding are different entities with different workups. Within reproductive-age women, age stratifies the workup: adolescents need coagulopathy screening (von Willebrand disease prevalence ~13–34% in adolescents with HMB) ACOG 2019; perimenopausal women (40–55) need endometrial sampling. The entry is scoped to adult women 18–55.
Credibility range
Optimist case
HMB is one of the most treatable common conditions in women's health. The 80 mL/cycle definition has 60 years of population-data backing; the PBAC chart is a validated practical surrogate; PALM-COEIN gives a comprehensive causal framework; multiple Cochrane-level interventions reduce bleeding by 40–95%; primary-care RCTs (ECLIPSE) demonstrate effectiveness in routine NHS settings out to 10 years. The downstream iron-deficiency cost is well-characterised, and iron repletion is cheap and effective. The under-recognition is largely a healthcare-utilisation problem (women don't present) rather than a treatment-efficacy problem.
Skeptic case
The category is partly an artefact of measurement. Subjective definitions yield prevalence rates anywhere from 15% to 52%; objective measurement is impractical outside trials; the PBAC chart is observer-dependent. Many of the trial endpoints are surrogate (mL/cycle, PBAC score) rather than felt-experience; the gap between bleeding reduction and quality-of-life improvement is variable across women. LNG-IUS has a real expulsion rate (~5–10%) and a real early-side-effects burden (irregular bleeding, hormonal symptoms) that drives discontinuation. Endometrial ablation has a substantial reintervention rate. The iron-deficiency-without-anemia symptom story is more contested than the anemia story — fatigue is multifactorial and ferritin's symptom threshold isn't universally agreed.
Author's call
The substance, its consequences, and its treatability are well-established — high evidence (5/5). The diagnostic side is contested mostly at the edges (where the cutoff sits, which subjective measure to use), not on the substance. The skeptic's reasonable points argue for individualised choice between LNG-IUS / tranexamic acid / surgery rather than against treatment per se. The under-recognition fact is the lever: a reader who learns that heavy periods are a treatable medical condition, not a personality trait, can act. Treat as know + decide: recognise it, get the workup, choose the treatment with a clinician.
Stakeholder and incentive map
- Manufacturers — Bayer (Mirena), Pfizer (Lysteda — branded tranexamic acid), AbbVie (Oriahnn — elagolix combination), Myovant/Sumitomo (Myfembree — relugolix combination) all market HMB-specific products. Incentive: maximise prescription. Commercial bias in funded trials is real but the underlying mechanism + Cochrane evidence is independent.
- Guidelines bodies — NICE, ACOG, FIGO, RCOG have aligned recommendations. NICE's QoL-based definition has shifted clinical practice toward patient-centered diagnosis.
- Clinicians — primary care undertreats (limited time, normalisation by both patient and clinician); gynecology sees the referrals later in the trajectory. Surgical specialties have a structural bias toward procedural intervention.
- Patient community — strong online presence (r/menorrhagia, period-tracking apps with HMB modules) increasingly normalising the "this is treatable" message; advocacy from women's-health organisations (Wear White Again, Period.org).
- Counter — historical undertreatment is itself a stakeholder force: a default frame of "periods are uncomfortable for everyone" that older healthcare provider cohorts may carry.
Population variability
- Adolescents — coagulopathy prevalence highest; up to ~34% have an underlying bleeding disorder when systematically tested ACOG 2019. Out of scope for this entry but flagged.
- Perimenopausal women (40–55) — fibroids and adenomyosis prevalence peaks; ovulatory dysfunction common; endometrial cancer risk rises so biopsy threshold drops.
- Women with PCOS — anovulatory cycles produce unopposed estrogen and irregular heavy episodes; progestin therapy addresses both.
- Black women — fibroid prevalence ~3× higher than white women, earlier onset, larger fibroids, more symptomatic Stewart 2015. HMB burden is correspondingly higher.
- Women with inherited bleeding disorders — von Willebrand disease (5–24% of HMB referrals) James 2009, platelet function disorders, factor deficiencies. Standard medical treatment efficacy is broadly preserved with hematology co-management.
- Postpartum women — adenomyosis and fibroids often progress with parity; HMB onset or worsening post-childbirth is common.
Knowledge gaps
- The ferritin threshold below which iron deficiency causes symptoms — research moving from <15 μg/L toward <30–50 μg/L but consensus incomplete.
- Long-term comparative effectiveness data for newer GnRH-antagonist combinations (relugolix, elagolix) vs. LNG-IUS for fibroid-associated HMB.
- How much of HMB-attributable fatigue is iron-mediated versus blood-loss-volume-mediated versus cycle-disruption-mediated.
- The natural history of HMB into perimenopause — when to treat and when to manage symptomatically.
- Pragmatic biomarkers beyond ferritin (transferrin saturation, soluble transferrin receptor) that better track functional iron status.
Scope vs. brief. Brief named: definitions, treatable causes including fibroids and adenomyosis, effects on iron stores, energy, daily function, quality of life. Article covers all six. Causes are treated comprehensively via PALM-COEIN framing rather than only fibroids + adenomyosis; this is the editorially honest read of the brief's "treatable causes including..." phrasing.
Adolescent HMB excluded. Brief specifies adult women. Adolescent HMB has a different presentation profile (much higher coagulopathy prevalence), different first-line workup emphasis (von Willebrand screening before structural workup), and different treatment menu (LNG-IUS less commonly used). Flagged in research §population variability; warrants its own entry.
Pregnancy-related bleeding, postmenopausal bleeding excluded. These are distinct entities with different workups (cancer rule-out for postmenopausal, obstetric for pregnancy). The contraindications section's red-flag list points readers with postmenopausal bleeding to a faster clinical track.
Rating difficulties.
- Beauty dimensions scored 1. Hair shedding from iron deficiency is real and reverses with treatment, but the magnitude is modest and the timescale is months. Considered 2 on beauty_cumulative but the effect is slow and not always reliably reversible past a threshold; 1 reads more honest.
- Action = know vs. decide. The reader-facing action is recognition (the brief's emphasis on under-diagnosis and women not knowing they qualify); treatment selection is then a decide. Chose
knowbecause the upstream action is the bigger lever — most women never reach the decide step. - Cadence = as-needed. The action is a one-off recognition-and-evaluation. Treatment itself is daily (iron), episodic (tranexamic acid), or passive (LNG-IUS), but the entry-level action is once.
- Audience age band excludes 60+. By definition HMB is in menstruating women. Postmenopausal bleeding is a separate, oncology-flagged entity. Including 60+ would broaden the audience signal misleadingly.
Iron deficiency without anaemia — load-bearing in the stakes section. The ferritin-vs-haemoglobin distinction is the single most actionable thing in the article for readers whose bloodwork has been called "normal" for years. Considered making this a separate entry; decided it belongs inside HMB because HMB is the dominant upstream cause and the recognition-action chain only works if the iron story is told here. A separate iron-deficiency-without-anaemia entry is flagged for the backlog (referenced in out-of-scope).
Future-link candidates (referenced in the closing addressing section, not yet existing):
iron-deficiency-without-anemiairon-supplementationdysmenorrheaendometriosisuterine-fibroids(this entry overlaps but fibroid-specific treatment menu warrants its own entry)adenomyosis(same — sibling entry candidate)pcosperimenopause
Separate-entry candidates surfaced during writing: uterine fibroids and adenomyosis are both substantial enough to warrant their own entries; this one frames them as upstream causes and points outward. The fibroid-treatment menu (myomectomy, UAE, GnRH-modulators including relugolix and elagolix combinations) is not unpacked here for that reason.
Controversy score = 1. Field consensus is broad. The genuine debates — subjective vs. objective definitional threshold, ferritin cutoff for symptom attribution, optimal first-line treatment between LNG-IUS and oral options — are real but minor and don't change the recognition-and-treat message.
Evidence score = 5. Two named RCTs (ECLIPSE, Lukes 2010), two named Cochrane reviews (2019 NSAIDs, 2020 LNG-IUS), aligned NICE + ACOG guidelines, 60-year population evidence backing the objective definition. Clears the "name 2+ rigorous trials" bar.
Heavy Menstrual Bleeding
Settled territory. Decades of trials, aligned international guidelines, treatments that work in routine clinic settings.
Treatment cuts bleeding by 70-90% and refills iron stores within months. Most women feel like a different person.
Heavy periods are the number-one cause of low iron in women under 50. Low iron is why you're tired, and it fixes.
Most treatments are cheap (a few pills during your period) or covered. The hormonal IUD pays for itself in five years.
A clinic visit and a blood test to start. Day-to-day, treatment is mostly passive — a fitted device or pills during periods only.
The brain runs badly on low iron — attention slips, memory blurs. Treat the bleeding, refill the iron, the fog lifts.
The dread of the next period, the housebound days, the low-iron mood — all real, all documented, all reversible.
Overnight changes interrupt sleep on heavy nights, and low iron causes restless legs. Both improve once treated.
Chronic blood loss thins hair and washes out skin colour; treat the bleeding and both come back.
Years of iron-depleted tissue leave a mark on skin and hair quality. Refilling the iron stores reverses most of it slowly.
Mostly catches the perimenopausal cancers that present as heavy bleeding, and prevents the rare severe-anemia hospitalisation.